Friday, July 10, 2026
🇺🇸 FDA

Drug profile · INN

aliskiren

RASILEZ

aliskiren (RASILEZ) is a renin inhibitor. Associated with Lxo Ireland Designated Activity Company.

EMA: approved Cardiovascular system (C09) C09XA02
Patents linked 20
Pipeline programs 3
News articles 0
Drug details — aliskiren
Class
Cardiovascular system (C09)
Route
—
Patents
20
Programs
3
Data quality
0.89
← All drugs Manufacturer profile Related patents Pipeline programs Drug news hub Event calendar

Quick answer

aliskiren (RASILEZ) is a renin inhibitor. Associated with Lxo Ireland Designated Activity Company.

Key facts

INN aliskiren
Brand RASILEZ
Mechanism Renin inhibitor
Therapeutic class Cardiovascular system (C09)
ATC code C09XA02
Originator Lxo Ireland Designated Activity Company

Mechanism of action

Renin inhibitor

Approval history

Authority Status Date
EMA approved —

Pipeline programs

Search pipeline Sponsor programs
  1. Aliskiren Phase 3 · Novartis India · Acute Decompensated Heart Failure
  2. Aliskiren Approved · Novartis India · Hypertension
  3. Aliskiren Approved · United Therapeutics Europe · IgA Nephropathy

Related & competitor drugs

Browse all drugs
  1. alirocumab Cardiovascular system (C10)
  2. azilsartan medoxomil Cardiovascular system (C09)
  3. bempedoic acid Cardiovascular system (C10)
  4. bosentan Cardiovascular system (C02)
  5. dofetilide Cardiovascular system (C01)
  6. dopamine hydrochloride Cardiovascular system (C01)

Related patents

Browse patents Lxo Ireland Designated Activity Company patent hub

  1. US 11911502

    Pharmaceutical compositions and methods of using the same

    Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11883420

    Sting agonists for treating bladder cancer and solid tumors

    Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11738015

    Pharmaceutical compositions and methods of using the same

    Expires Mon Aug 24 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11654128

    Methods and compositions for treating ectoparasite infestations

    Expires Mon May 18 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11505525

    Branched discrete PEG constructs

    Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11479769

    Technique for treating cancer using structurally-reinforced S-TuD

    Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11365230

    Compositions comprising lentiviral vectors expressing IL-12 and methods of use thereof

    Expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11268098

    Non-aggregating immunostimulatory oligonucleotides

    Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11236055

    Non-systemic TGR5 agonists

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11161864

    Sting agonists

    Expires Mon Oct 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11110106

    Sting agonists for treating bladder cancer and solid tumors

    Expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10993999

    Materials and methods for producing improved lentiviral vector particles

    Expires Mon Apr 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10967346

    Microspheres and method for producing them

    Expires Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10913888

    Nanotube mediation of degradative chemicals for oil-field application

    Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10654834

    Non-systemic TGR5 agonists

    Expires Mon May 14 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10414655

    Stem cell, bone, tissue and nerve scaffolding from discrete carbon nanotubes

    Expires Mon Sep 12 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10391157

    Materials and methods for producing improved lentiviral vector particles

    Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10369118

    Method of reducing scarring

    Expires Mon Aug 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10124109

    Method and device for treating allergic reactions and difficult-to-manage respiratory diseases

    Expires Mon Nov 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10099995

    Resveratrol esters

    Expires Mon Oct 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is aliskiren?

aliskiren (RASILEZ) is a renin inhibitor. Associated with Lxo Ireland Designated Activity Company.

What is the brand name for aliskiren?

RASILEZ is a marketed brand name for aliskiren. Check FDA Drugs@FDA for the current US label holder and prescribing information.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.